Delta-like protein 4/DLL4 Protein, Human (HEK293)

Delta-like protein 4 (DLL4) functions as a Notch ligand and activates NOTCH1 and NOTCH4 in the Notch signaling pathway. It regulates angiogenesis by inhibiting endothelial cell proliferation, migration, and angiogenesis. Delta-like protein 4/DLL4 Protein, Human (HEK293) is the recombinant human-derived Delta-like protein 4/DLL4 protein, expressed by HEK293 , with tag free.

Delta-like protein 4 (DLL4) is a key participant in the Notch signaling pathway, acting as a Notch ligand with functional implications. It specifically activates NOTCH1 and NOTCH4, contributing to the intricate cellular communication within this signaling cascade. Beyond its role in Notch signaling, DLL4 emerges as a crucial regulator of angiogenesis, exerting a negative influence on endothelial cell proliferation, migration, and angiogenic sprouting. The protein's indispensability extends to retinal progenitor proliferation, where it plays a vital role in suppressing rod fates in late retinal progenitors and ensuring the proper generation of diverse retinal cell types. Additionally, during spinal cord neurogenesis, DLL4 inhibits V2a interneuron fate, adding another layer to its multifaceted functions. The molecular interactions involving DLL4 include its engagement with NOTCH4 and NOTCH1, facilitated by specific domains in DLL4 and NOTCH1, respectively.

Immobilized Human DLL4, No Tag at 0.5 μg/mL (100 μl/well) on the plate. Dose response curve for Anti-DLL4 Antibody, hFc Tag with the EC₅₀ of ≤8.8 ng/mL determined by ELISA.

• 
  Immobilized Recombinant Human DLL4 Protein at 0.5 μg/mL can bind Anti-DLL4 Antibody. The ED₅₀ for this effect is 2.447 ng/mL.

Human

HEK293

Tag Free

Q9NR61 (S27-P524)

54567  [NCBI]

Partial

SGVFQLQLQEFINERGVLASGRPCEPGCRTFFRVCLKHFQAVVSPGPCTFGTVSTPVLGTNSFAVRDDSSGGGRNPLQLPFNFTWPGTFSLIIEAWHAPGDDLRPEALPPDALISKIAIQGSLAVGQNWLLDEQTSTLTRLRYSYRVICSDNYYGDNCSRLCKKRNDHFGHYVCQPDGNLSCLPGWTGEYCQQPICLSGCHEQNGYCSKPAECLCRPGWQGRLCNECIPHNGCRHGTCSTPWQCTCDEGWGGLFCDQDLNYCTHHSPCKNGATCSNSGQRSYTCTCRPGYTGVDCELELSECDSNPCRNGGSCKDQEDGYHCLCPPGYYGLHCEHSTLSCADSPCFNGGSCRERNQGANYACECPPNFTGSNCEKKVDRCTSNPCANGGQCLNRGPSRMCRCRPGFTGTYCELHVSDCARNPCAHGGTCHDLENGLMCTCPAGFSGRRCEVRTSIDACASSPCFNRATCYTDLSTDTFVCNCPYGFVGSRCEFPVGLP

Approximately 55-73 kDa, based on SDS-PAGE under reducing conditions, due to the glycosylation.

• 
  ≥ 95%, as determined by reducing SDS-PAGE.

Lyophilized powder

1.Lyophilized from 0.22 μm filtered solution in PBS, 200 mM Arginine, pH 7.4, 8% trehalose.
2.Lyophilized from 0.22 μm filtered solution in PBS, 200 mM Arginine, pH 7.4.
Please refer to the lot-specific COA for specific buffer information.

<1 EU/μg, determined by LAL method.

It is not recommended to reconstitute to a concentration less than 100 μg/mL in ddH₂O. For long term storage it is recommended to add a carrier protein (0.1% BSA, 5% HSA, 10% FBS or 5% Trehalose).

Stored at -20°C for 2 years from date of receipt. After reconstitution, it is stable at 4°C for 1 week or -20°C for longer (with carrier protein). It is recommended to freeze aliquots at -20°C or -80°C for extended storage.

Room temperature in continental US; may vary elsewhere.

• [1]. /biology-dictionary/cho-k1-cell.html  [Content Brief]